文献速递慢性静脉疾病

肥胖对慢性静脉功能不全治疗结局的影响

Effect of obesity on chronic venous insufficiency treatment outcomes.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-04-23

研究回顾性分析2015至2017年65329例接受静脉手术患者,按BMI分组评估腔内热消融、静脉切除术或超声引导泡沫硬化治疗的效果。结果显示BMI越高,术后6个月修订静脉临床严重程度评分和CIVIQ-20改善越差,BMI≥35 kg/m2者结局显著 inferior,BMI≥46 kg/m2者最差,建议治疗前考虑体重管理。

要点

  • BMI>35 kg/m2患者接受慢性静脉疾病治疗后结局进行性恶化。
  • BMI≥46 kg/m2患者结局最差,治疗前应考虑体重管理。
  • 热消融联合静脉切除术可改善结局约12%,但三联治疗无额外改善。

核心结论

  • BMI进行性增加对慢性静脉疾病治疗结局产生负面影响,以修订静脉临床严重程度评分和CIVIQ-20衡量。
  • BMI>35 kg/m2患者结局进行性恶化,BMI≥46 kg/m2患者结局极差,治疗前应考虑体重管理。

研究设计与样本

  • 前瞻性收集静脉修复中心电子病历数据并回顾性分析。
  • 2015年1月至2017年12月,65329例患者(77%女性,23%男性)接受静脉手术,其中25592例(39919条肢体)接受消融、消融加静脉切除术或消融加静脉切除术加超声引导泡沫硬化治疗。
  • 按BMI分组:<25、26-30、31-35、36-40、41-45、>46 kg/m2。

主要发现

  • 热消融患者术后6个月改善程度随BMI增加而进行性降低,BMI>35 kg/m2者下降更显著(P ≤ .001)。
  • 热消融联合静脉切除术使结局改善约12%,但联合超声引导泡沫硬化治疗无额外改善。
  • BMI≥35 kg/m2患者结局显著较差,BMI≥46 kg/m2者最差(P ≤ .001)。
  • 平均每例患者热消融次数随BMI增加而增加,与BMI<30 kg/m2者相比差异显著(P ≤ .001)。
  • 多变量logistic回归分析显示,控制BMI后,糖尿病、癌症史、女性、黑人和西班牙裔种族与较差结局独立相关。

关键数值与推荐

  • 热消融患者BMI>35 kg/m2时结局进行性恶化(P ≤ .001)。
  • BMI≥35 kg/m2患者结局显著较差,BMI≥46 kg/m2者最差(P ≤ .001)。
  • 热消融联合静脉切除术使结局改善约12%。
  • 同一BMI组内,术前和术后6个月CIVIQ-20生活质量评分均显著不同(P ≤ .01)。
  • BMI≥31 kg/m2患者改善程度无差异。

临床怎么用

  • 对BMI≥46 kg/m2的慢性静脉疾病患者,考虑在治疗前进行体重管理。
  • 热消融联合静脉切除术可改善结局,但联合泡沫硬化治疗无额外获益。
  • BMI较高患者可能需要更多次热消融治疗。

局限性

  • 回顾性分析电子病历数据,可能存在选择偏倚和信息偏倚。
  • 未报告具体混杂因素控制方法和失访情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a known risk factor for the development and progression of chronic venous disorders (CVDs). It is currently unknown whether the treatment outcomes, after an intervention for CVDs, are affected by obesity. The purpose of the present investigation was to assess the effectiveness of various CVD treatments in obese patients and determine what level of obesity is associated with poor outcomes. METHODS: Data were prospectively collected in the Center for Vein Restoration electronic medical record system (NexGen Healthcare Information System, Irvine, Calif) and retrospectively analyzed. The patients and limbs were categorized by the following body mass index (BMI) categories: <25, 26 to 30, 31 to 35, 36 to 40, 41 to 45, and >46 kg/m2. The changes in the revised venous clinical severity score and Chronic Venous Insufficiency Quality of Life Questionnaire 20-item (CIVIQ-20) quality of life survey were used to determine the CVD treatment effectiveness for patients who had undergone endovenous thermal ablation (TA), phlebectomy, or ultrasound-guided foam sclerotherapy (USGFS). RESULTS: From January 2015 to December 2017, 65,329 patients (77% female; 23% male) had undergone a venous procedure. Of these patients, 25,592 (39,919 limbs) had undergone ablation alone, ablation with phlebectomy, or ablation with phlebectomy and USGFS. The number of procedures performed was as follows: TA, n = 37,781; USGFS, n = 22,964; and phlebectomy, n = 17,467. The degree of improvement at 6 months after the procedure was progressively less with an increasing BMI for the patients who had undergone TA, and the decrease was more significant for those patients with a BMI >35 kg/m2 (P ≤ .001). The outcomes improved ∼12% with the addition of phlebectomy to TA. The patients who had undergone a combination of TA, phlebectomy, and USGFS demonstrated no additional improvement. Significantly inferior outcomes were noted in patients with a BMI ≥35 kg/m2, with the poorest outcomes observed in patients with a BMI ≥46 kg/m2 (P ≤ .001). The average number of TAs per patient increased with an increasing BMI and was significantly different compared with the number for those with a BMI <30 kg/m2 (P ≤ .001). All pre- and post-CIVIQ-20 quality of life scores, within a BMI category, at 6 months were significantly different (P ≤ .01). No differences in the degree of improvement were observed in patients with a BMI ≥31 kg/m2. Finally, multivariate logistic regression analysis indicated that when controlling for BMI, diabetes, a history of cancer, female gender, and black and Hispanic race were independently associated with poorer outcomes. CONCLUSIONS: Progressive increases in BMI negatively affected CVD-related treatment outcomes as measured using the revised venous clinical severity score and CIVIQ-20. The outcomes progressively worsened with a BMI >35 kg/m2 for patients undergoing CVD treatment. The treatment outcomes for patients with a BMI ≥46 kg/m2 were so poor that weight loss management should be considered before offering CVD treatment.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Deol ZK, Lakhanpal S, Franzon G, et al. Effect of obesity on chronic venous insufficiency treatment outcomes. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32335333. doi:10.1016/j.jvsv.2020.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。